165 related articles for article (PubMed ID: 35483739)
21. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion.
Simpkins F; Papadia A; Kunos C; Michener C; Frasure H; AbuShahin F; Mariani A; Bakkum-Gamez JN; Landrum L; Moore K; Thomas SG; Windhorn A; Rose PG
Int J Gynecol Cancer; 2013 Jan; 23(1):98-104. PubMed ID: 23221731
[TBL] [Abstract][Full Text] [Related]
22. Ultrastaging of 'negative' pelvic lymph nodes in patients with low- and intermediate-risk endometrioid endometrial cancer who developed non-vaginal recurrences.
Gill SE; Garzon S; Multinu F; Hokenstad AN; Casarin J; Cappuccio S; McGree ME; Weaver AL; Cliby WA; Keeney GL; Mariani A
Int J Gynecol Cancer; 2021 Dec; 31(12):1541-1548. PubMed ID: 34706876
[TBL] [Abstract][Full Text] [Related]
23. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
van den Heerik ASVM; Horeweg N; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld GH; van den Berg HA; Slot A; Koppe FLA; Kommoss S; Mens JWM; Nowee ME; Bijmolt S; Cibula D; Stam TC; Jurgenliemk-Schulz IM; Snyers A; Hamann M; Zwanenburg AG; Coen VLMA; Vandecasteele K; Gillham C; Chargari C; Verhoeven-Adema KW; Putter H; van den Hout WB; Wortman BG; Nijman HW; Bosse T; Creutzberg CL
Int J Gynecol Cancer; 2020 Dec; 30(12):2002-2007. PubMed ID: 33046573
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis.
Travaglino A; Raffone A; Raimondo D; Reppuccia S; Ruggiero A; Arena A; Casadio P; Zullo F; Insabato L; Seracchioli R; Mollo A
Arch Gynecol Obstet; 2022 Aug; 306(2):423-431. PubMed ID: 35034160
[TBL] [Abstract][Full Text] [Related]
25. Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer.
Garzon S; Grassi T; Mariani A; Kollikonda S; Weaver AL; McGree ME; Petersen IA; Weroha SJ; Glaser GE; Langstraat CL; Amarnath SR; AlHilli MM
Gynecol Oncol; 2022 Dec; 167(3):444-451. PubMed ID: 36244826
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study.
Kurnit KC; Nobre SP; Fellman BM; Iglesias DA; Lindemann K; Jhingran A; Eriksson AGZ; Ataseven B; Glaser GE; Mueller JJ; Westin SN; Soliman PT
Gynecol Oncol; 2022 Dec; 167(3):452-457. PubMed ID: 36243601
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?
Beavis AL; Yen TT; Stone RL; Wethington SL; Carr C; Son J; Chambers L; Michener CM; Ricci S; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan AN; Jager LR; Fader AN
Gynecol Oncol; 2020 Mar; 156(3):568-574. PubMed ID: 31948730
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study.
Kuku S; Williams M; McCormack M
Int J Gynecol Cancer; 2013 Jul; 23(6):1056-64. PubMed ID: 23765205
[TBL] [Abstract][Full Text] [Related]
29. Role of brachytherapy in stage III endometrial cancer treated with adjuvant chemotherapy: Identifying factors predictive of a survival benefit.
Xiang M; English DP; Kidd EA
Brachytherapy; 2021; 20(4):701-709. PubMed ID: 33781714
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer.
Chapman BV; Swanick CW; Ning MS; Allen PK; Soliman PT; Westin SN; Pardeshi V; Broaddus RR; Lu KH; Jhingran A; Eifel PJ; Klopp AH
Gynecol Oncol; 2019 Jul; 154(1):22-28. PubMed ID: 31109659
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic Evaluation of CTNNB1 Mutations in High-Intermediate Risk Endometrial Endometrioid Carcinoma.
Haag JG; Wolsky RJ; Moroney MR; Sheren J; Sheeder J; Bitler BG; Corr BR
Int J Gynecol Pathol; 2023 Jan; 42(1):43-53. PubMed ID: 35283443
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant Radiation Field Extent and Sites of Failure in Node Positive Endometrioid Endometrial Cancer.
Yerramilli D; Chen YH; Venkatachalam V; Alban GM; Buscariollo DL; Cheng T; King MT; Pretz JL; Russo AL; Lee LJ
Pract Radiat Oncol; 2021; 11(5):394-403. PubMed ID: 34015544
[TBL] [Abstract][Full Text] [Related]
33. Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
Philp L; Tannenbaum S; Haber H; Saini A; Laurent JS; James K; Feltmate CM; Russo AL; Growdon WB
Gynecol Oncol; 2021 Feb; 160(2):389-395. PubMed ID: 33358198
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant chemotherapy and radiation for patients with high-risk stage I endometrial cancer treated with curative intent surgery: impact on recurrence and survival.
Findley R; Kooy J; Lester B; Le ND; Bowering G; Rugayan C; Kumar A; Glaze S; Ko J
Int J Gynecol Cancer; 2022 Apr; 32(4):508-516. PubMed ID: 35078828
[TBL] [Abstract][Full Text] [Related]
35. Unique prognostic features of grade 3 endometrioid endometrial carcinoma: Findings from 101 consecutive cases at a Japanese tertiary cancer center.
Kato MK; Yoshida H; Uehara T; Uno M; Ishikawa M; Miyasaka N; Kato T
Taiwan J Obstet Gynecol; 2021 Mar; 60(2):238-244. PubMed ID: 33678322
[TBL] [Abstract][Full Text] [Related]
36. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
37. The effect of complete surgical staging and adjuvant chemotherapy on survival in stage I, grade 1 and 2 endometrioid ovarian carcinoma.
Swift BE; Covens A; Mintsopoulos V; Parra-Herran C; Bernardini MQ; Nofech-Mozes S; Hogen L
Int J Gynecol Cancer; 2022 Apr; 32(4):525-531. PubMed ID: 34969829
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma.
Costigan DC; Dong F; Nucci MR; Howitt BE
Int J Gynecol Pathol; 2020 Mar; 39(2):119-127. PubMed ID: 30702464
[TBL] [Abstract][Full Text] [Related]
39. Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
Backes FJ; Felix AS; Plante M; Grégoire J; Sullivan SA; Rossi EC; Tanner EJ; Stewart KI; Soliman PT; Holloway RW; Abu-Rustum NR; Leitao MM
Gynecol Oncol; 2021 May; 161(2):347-352. PubMed ID: 33678480
[TBL] [Abstract][Full Text] [Related]
40. Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist's point of view.
Foerster R; Kluck R; Arians N; Rieken S; Rief H; Adeberg S; Bostel T; Schlampp I; Debus J; Lindel K
Radiat Oncol; 2015 Jul; 10():147. PubMed ID: 26179059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
